Pharmacological treatment of chronic heart failure

Rachele Adorisio, Leonardo De Luca, Joseph Rossi, Mihai Gheorghiade

Research output: Contribution to journalArticlepeer-review


Heart failure (HF) is associated with a high morbidity and mortality in the Western World. Our knowledge of the epidemiology, pathophysiology, and therapy has improved dramatically during the last 20 years. Pharmacological treatment, as it stands today, is a combination of preventive and symptomatic strategies. The mainstay life-saving drugs are angiotensin-converting enzyme inhibitors and β-blockers. Additional benefits are obtained when angiotensin-receptor blockers or aldosterone antagonists are added. Digitalis and/or diuretics are useful for symptom reduction. In addition, combination therapy with hydralazine and isosorbide dinitrate is recommended in African Americans.

Original languageEnglish
Pages (from-to)109-123
Number of pages15
JournalHeart Failure Reviews
Issue number2
Publication statusPublished - Jun 2006


  • β-blockers
  • Angiotensin-converting enzyme inhibitors
  • Digitalis
  • Diuretics
  • Drugs
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Pharmacological treatment of chronic heart failure'. Together they form a unique fingerprint.

Cite this